The MEDICREA Group (FR0004178572-ALMED) (Paris:ALMED), listed on Alternext by NYSE Euronext Paris, a medical device company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, reaffirmed its ambitious marketing schedule today for GRANVIA®-C, its next-generation cervical disc prosthesis, and also announced the launch of a pre-IDE pilot trial with a view to initiating the approval process in the United States.
